000 01220nam a2200337 a 4500
005 20250918125958.0
008 110310s2009 xxka 001 0 eng
020 _a9780470060858
_cRM310.07
039 9 _a201103151545
_bjufri
_c201103110927
_dbalqis
_y03-10-2011
_zbalqis
040 _dUKM
060 _aQV771
_b.M985b 2009 9HUKM
090 _aQV771.M985b 2009 9HUKM[00099000911]
100 1 _aMussen, Filip
245 1 0 _aBenefit-risk appraisal of medicines :
_ba systematic approach to decision-making /
_cFilip Mussen, Sam Salek, Stuart Walker
260 _aChichester :
_bWiley-Blackwell,
_c2009
300 _ax, 294 p. :
_bill. ;
_c25 cm.
504 _aReferences : p. 271-283
650 2 _aDrug Evaluation
_xstandards
650 2 _aRisk assessment
650 2 _aDecision Support Techniques
650 2 _aModels, Theoretical
700 1 _aSalek, Sam
700 1 _aWalker, Stuart,
_d1944-
907 _a.b14960679
_b2019-11-12
_c2019-11-12
942 _c01
_n0
_kQV771.M985b 2009 9HUKM[00099000911]
914 _avtls003457982
990 _aNHR/jufri
991 _aJabatan Institut Perubatan Biologi Molekular (UMBI), PPUKM
998 _ah
_b2011-10-03
_cm
_da
_feng
_gxxk
_y0
_z.b14960679
999 _c480909
_d480909